Physician profile
Krishnaiah Rayasam
NPI 1831188903
$3,379.22
in general payments reported to CMS, 2019-2025
17 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $407 · 2021: $743 · 2022: $552 · 2023: $289 · 2024: $588 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.17 |
| Education | $182.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $678.46 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $500.32 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $471.41 | 2020-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $376.23 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $329.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $303.67 | 2020-2024 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.97 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $167.70 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $91.22 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $78.07 | 2019 | |
| Abbvie INC. | $68.69 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $32.03 | 2019-2024 | Fanapt |
| Allergan, INC. | $29.99 | 2020 | |
| Corium, LLC | $28.71 | 2023 | Azstarys |
| Eisai INC. | $21.98 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $13.53 | 2025 | Onyda Xr |
| Rhodes Pharmaceuticals L.P. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnaiah Rayasam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.